Masafumi Yonezaki1, Kosuke Akiyama2, Masayuki Karaki3, Rieko Goto4, Rhyuhei Inamoto5, Yasushi Samukawa4, Ryuichi Kobayashi6, Eiji Kobayashi7, Hiroshi Hoshikawa5. 1. Department of Otolaryngology, Utinomi Hospital, Syouzu-gun, Syoudoshima-cho, Henjyoko 44-95, Kagawa 761-4431, Japan; Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan. 2. Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan. Electronic address: kakaka@med.kagawa-u.ac.jp. 3. Tanaka ENT Clinic, Tyuou-ku, Shinshigai 7-17, Kumamoto 860-0803, Japan. 4. Department of Otolaryngology, Mitoyo General Hospital, Mitoyo-shi, Toyohama-cho, Himehama 708, Kagawa 769-1695, Japan. 5. Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan. 6. Department of Otolaryngology, Ayagawa National Health Insurance Sue Hospital, Ayauta-gun, Ayagawa-cho, Sue 1720-1, Kagawa 761-2103, Japan. 7. Kobayashi ENT Clinic, Higashi Kagawa-shi, Sanbonmatsu 1887-1, Kagawa 769-2601, Japan.
Abstract
OBJECTIVE:Intranasal corticosteroid sprays (INCSs) are commonly used for therapy of allergic rhinitis (AR). Adherence to regular use of INCSs is influenced by patient perception and preferences of products. The study objective was to compare perceived sensory attributes of fluticasone furoate nasal spray (FFNS) and mometasone furoate nasal spray (MFNS) in AR patients. METHODS: In a multicenter, randomized, crossover, prospective study, 40 seasonal AR patients were administered both FFNS and MFNS for 2 weeks each in a crossover fashion, for a total of 4 weeks. Patients completed questionnaires for each product regarding perceived sensory attributes at the end of each two-week period of product administration. RESULTS:FFNS was significantly preferred over MFNS. Significantly, fewer subjects perceived a bitter taste (p=0.01), medication running down their throat (p=0.033), and medication running out of their nose (p=0.002) with FFNS. MFNS was more frequently reported to induce nasal irritation (p=0.012), sneezing (p=0.017), and rhinorrhea (p=0.007) compared to FFNS. Interestingly, these findings were markedly observed in females. Medicine dripping out of the nose and nasal shooting were the most common problems reported for MFNS with a higher proportion of subjects who felt moderate-to-severe discomfort. Overall, 52.5% of patients expressed a preference for FFNS compared with 22.5% for MFNS. CONCLUSION: Several perceived sensory attributes of FFNS were rated significantly superior to MFNS. FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence.
RCT Entities:
OBJECTIVE: Intranasal corticosteroid sprays (INCSs) are commonly used for therapy of allergic rhinitis (AR). Adherence to regular use of INCSs is influenced by patient perception and preferences of products. The study objective was to compare perceived sensory attributes of fluticasone furoate nasal spray (FFNS) and mometasone furoate nasal spray (MFNS) in AR patients. METHODS: In a multicenter, randomized, crossover, prospective study, 40 seasonal AR patients were administered both FFNS and MFNS for 2 weeks each in a crossover fashion, for a total of 4 weeks. Patients completed questionnaires for each product regarding perceived sensory attributes at the end of each two-week period of product administration. RESULTS:FFNS was significantly preferred over MFNS. Significantly, fewer subjects perceived a bitter taste (p=0.01), medication running down their throat (p=0.033), and medication running out of their nose (p=0.002) with FFNS. MFNS was more frequently reported to induce nasal irritation (p=0.012), sneezing (p=0.017), and rhinorrhea (p=0.007) compared to FFNS. Interestingly, these findings were markedly observed in females. Medicine dripping out of the nose and nasal shooting were the most common problems reported for MFNS with a higher proportion of subjects who felt moderate-to-severe discomfort. Overall, 52.5% of patients expressed a preference for FFNS compared with 22.5% for MFNS. CONCLUSION: Several perceived sensory attributes of FFNS were rated significantly superior to MFNS. FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence.
Authors: Anahi Yanez; Alex Dimitroff; Peter Bremner; Chae-Seo Rhee; Graham Luscombe; Barbara A Prillaman; Neil Johnson Journal: Allergy Rhinol (Providence) Date: 2016-01-01